Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers

Lisa Haley, Li Hui Tseng, Gang Zheng, Jonathan Dudley, Derek A. Anderson, Nilofer Azad, Christopher Gocke, James Eshleman, Ming-Tseh Lin

Research output: Contribution to journalArticle

Abstract

Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR) pathway may cause anti-EGFR resistance in patients with colorectal cancers. We present performance characteristics of a next-generation sequencing assay designed to detect such mutations. In this retrospective quality assessment study, we analyzed mutation detected in the KRAS, NRAS, BRAF, and PIK3CA genes by a clinically validated next-generation sequencing assay in 310 colorectal cancer specimens. Tumor cellularity and mutant allele frequency were analyzed to identify tumor heterogeneity and mutant allele-specific imbalance. Next-generation sequencing showed precise measurement of mutant allele frequencies and detected 23% of mutations with 2-20% mutant allele frequencies. Of the KRAS mutations detected, 17% were outside of codons 12 and 13. Among PIK3CA mutations, 48% were outside of codons 542, 545, and 1047. The percentage of tumors with predicted resistance to anti-EGFR therapy increased from 40% when testing for only mutations in KRAS exon 2 to 47% when testing for KRAS exons 2-4, 48% when testing for KRAS and NRAS exons 2-4, 58% when including BRAF codon 600 mutations, and 59% when adding PIK3CA exon 20 mutations. Right-sided colorectal cancers carried a higher risk of predicted anti-EGFR resistance. A concomitant KRAS mutation was detected in 51% of PIK3CA, 23% of NRAS, and 33% of kinase-impaired BRAF-mutated tumors. Lower than expected mutant allele frequency indicated tumor heterogeneity, while higher than expected mutant allele frequency indicated mutant allele-specific imbalance. Two paired neuroendocrine carcinomas and adjacent adenomas showed identical KRAS mutations, but only PIK3CA mutations in neuroendocrine carcinomas. Next-generation sequencing is a robust tool for mutation detection in clinical laboratories. It demonstrates high analytic sensitivity and broad reportable range, and it provides simultaneous detection of concomitant mutations and a quantitative measurement of mutant allele frequencies to predict tumor heterogeneity and mutant allele-specific imbalance.

Original languageEnglish (US)
Pages (from-to)1390-1399
Number of pages10
JournalModern Pathology
Volume28
Issue number10
DOIs
StatePublished - Oct 3 2015

Fingerprint

Colorectal Neoplasms
Mutation
Gene Frequency
Exons
Epidermal Growth Factor Receptor
Codon
Neuroendocrine Carcinoma
Neoplasms
Alleles
Proto-Oncogene Proteins B-raf
erbB-1 Genes
Adenoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. / Haley, Lisa; Tseng, Li Hui; Zheng, Gang; Dudley, Jonathan; Anderson, Derek A.; Azad, Nilofer; Gocke, Christopher; Eshleman, James; Lin, Ming-Tseh.

In: Modern Pathology, Vol. 28, No. 10, 03.10.2015, p. 1390-1399.

Research output: Contribution to journalArticle

@article{57c8f43130694dbebb1602c985b5d924,
title = "Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers",
abstract = "Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR) pathway may cause anti-EGFR resistance in patients with colorectal cancers. We present performance characteristics of a next-generation sequencing assay designed to detect such mutations. In this retrospective quality assessment study, we analyzed mutation detected in the KRAS, NRAS, BRAF, and PIK3CA genes by a clinically validated next-generation sequencing assay in 310 colorectal cancer specimens. Tumor cellularity and mutant allele frequency were analyzed to identify tumor heterogeneity and mutant allele-specific imbalance. Next-generation sequencing showed precise measurement of mutant allele frequencies and detected 23{\%} of mutations with 2-20{\%} mutant allele frequencies. Of the KRAS mutations detected, 17{\%} were outside of codons 12 and 13. Among PIK3CA mutations, 48{\%} were outside of codons 542, 545, and 1047. The percentage of tumors with predicted resistance to anti-EGFR therapy increased from 40{\%} when testing for only mutations in KRAS exon 2 to 47{\%} when testing for KRAS exons 2-4, 48{\%} when testing for KRAS and NRAS exons 2-4, 58{\%} when including BRAF codon 600 mutations, and 59{\%} when adding PIK3CA exon 20 mutations. Right-sided colorectal cancers carried a higher risk of predicted anti-EGFR resistance. A concomitant KRAS mutation was detected in 51{\%} of PIK3CA, 23{\%} of NRAS, and 33{\%} of kinase-impaired BRAF-mutated tumors. Lower than expected mutant allele frequency indicated tumor heterogeneity, while higher than expected mutant allele frequency indicated mutant allele-specific imbalance. Two paired neuroendocrine carcinomas and adjacent adenomas showed identical KRAS mutations, but only PIK3CA mutations in neuroendocrine carcinomas. Next-generation sequencing is a robust tool for mutation detection in clinical laboratories. It demonstrates high analytic sensitivity and broad reportable range, and it provides simultaneous detection of concomitant mutations and a quantitative measurement of mutant allele frequencies to predict tumor heterogeneity and mutant allele-specific imbalance.",
author = "Lisa Haley and Tseng, {Li Hui} and Gang Zheng and Jonathan Dudley and Anderson, {Derek A.} and Nilofer Azad and Christopher Gocke and James Eshleman and Ming-Tseh Lin",
year = "2015",
month = "10",
day = "3",
doi = "10.1038/modpathol.2015.86",
language = "English (US)",
volume = "28",
pages = "1390--1399",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers

AU - Haley, Lisa

AU - Tseng, Li Hui

AU - Zheng, Gang

AU - Dudley, Jonathan

AU - Anderson, Derek A.

AU - Azad, Nilofer

AU - Gocke, Christopher

AU - Eshleman, James

AU - Lin, Ming-Tseh

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR) pathway may cause anti-EGFR resistance in patients with colorectal cancers. We present performance characteristics of a next-generation sequencing assay designed to detect such mutations. In this retrospective quality assessment study, we analyzed mutation detected in the KRAS, NRAS, BRAF, and PIK3CA genes by a clinically validated next-generation sequencing assay in 310 colorectal cancer specimens. Tumor cellularity and mutant allele frequency were analyzed to identify tumor heterogeneity and mutant allele-specific imbalance. Next-generation sequencing showed precise measurement of mutant allele frequencies and detected 23% of mutations with 2-20% mutant allele frequencies. Of the KRAS mutations detected, 17% were outside of codons 12 and 13. Among PIK3CA mutations, 48% were outside of codons 542, 545, and 1047. The percentage of tumors with predicted resistance to anti-EGFR therapy increased from 40% when testing for only mutations in KRAS exon 2 to 47% when testing for KRAS exons 2-4, 48% when testing for KRAS and NRAS exons 2-4, 58% when including BRAF codon 600 mutations, and 59% when adding PIK3CA exon 20 mutations. Right-sided colorectal cancers carried a higher risk of predicted anti-EGFR resistance. A concomitant KRAS mutation was detected in 51% of PIK3CA, 23% of NRAS, and 33% of kinase-impaired BRAF-mutated tumors. Lower than expected mutant allele frequency indicated tumor heterogeneity, while higher than expected mutant allele frequency indicated mutant allele-specific imbalance. Two paired neuroendocrine carcinomas and adjacent adenomas showed identical KRAS mutations, but only PIK3CA mutations in neuroendocrine carcinomas. Next-generation sequencing is a robust tool for mutation detection in clinical laboratories. It demonstrates high analytic sensitivity and broad reportable range, and it provides simultaneous detection of concomitant mutations and a quantitative measurement of mutant allele frequencies to predict tumor heterogeneity and mutant allele-specific imbalance.

AB - Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR) pathway may cause anti-EGFR resistance in patients with colorectal cancers. We present performance characteristics of a next-generation sequencing assay designed to detect such mutations. In this retrospective quality assessment study, we analyzed mutation detected in the KRAS, NRAS, BRAF, and PIK3CA genes by a clinically validated next-generation sequencing assay in 310 colorectal cancer specimens. Tumor cellularity and mutant allele frequency were analyzed to identify tumor heterogeneity and mutant allele-specific imbalance. Next-generation sequencing showed precise measurement of mutant allele frequencies and detected 23% of mutations with 2-20% mutant allele frequencies. Of the KRAS mutations detected, 17% were outside of codons 12 and 13. Among PIK3CA mutations, 48% were outside of codons 542, 545, and 1047. The percentage of tumors with predicted resistance to anti-EGFR therapy increased from 40% when testing for only mutations in KRAS exon 2 to 47% when testing for KRAS exons 2-4, 48% when testing for KRAS and NRAS exons 2-4, 58% when including BRAF codon 600 mutations, and 59% when adding PIK3CA exon 20 mutations. Right-sided colorectal cancers carried a higher risk of predicted anti-EGFR resistance. A concomitant KRAS mutation was detected in 51% of PIK3CA, 23% of NRAS, and 33% of kinase-impaired BRAF-mutated tumors. Lower than expected mutant allele frequency indicated tumor heterogeneity, while higher than expected mutant allele frequency indicated mutant allele-specific imbalance. Two paired neuroendocrine carcinomas and adjacent adenomas showed identical KRAS mutations, but only PIK3CA mutations in neuroendocrine carcinomas. Next-generation sequencing is a robust tool for mutation detection in clinical laboratories. It demonstrates high analytic sensitivity and broad reportable range, and it provides simultaneous detection of concomitant mutations and a quantitative measurement of mutant allele frequencies to predict tumor heterogeneity and mutant allele-specific imbalance.

UR - http://www.scopus.com/inward/record.url?scp=84942983135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942983135&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2015.86

DO - 10.1038/modpathol.2015.86

M3 - Article

C2 - 26226847

AN - SCOPUS:84942983135

VL - 28

SP - 1390

EP - 1399

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 10

ER -